Jazz targets US launch of SCLC drug after FDA grants fast review

Jazz targets US launch of SCLC drug after FDA grants fast review

Source: 
Pharmaforum
snippet: 

PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for relapsed small cell lung cancer (SCLC).